Table 1.
Clinical and demographic data for all (n = 25) participants
| Clinical & Demographic data | ||
| Mean (SD) | ||
| Age | 49 (15) | |
| Number of Esketamine-treatments | 11.4 (8) | |
| BDI II (all patients) pre treatment | 30.9 (13.25) | |
| unipolar | 33 | |
| bipolar | 25 | |
| schizoaffective | 36 | |
| BDI II (all patients) post treatment | 20.9 (13.75) | |
| unipolar | 24 | |
| bipolar | 12 | |
| schizoaffective | 25 | |
| Number of urine samples per patient | 11.2 (8) | |
| Percentages | ||
| Gender | male | 40% |
| female | 60% | |
| Primary Diagnosis | unipolar | 64% |
| bipolar | 28% | |
| schizoaffective | 8% | |
| Atrial Fibrillation | 4% | |
| Peripheral Polyneuropathy | 4% | |
| Obstructive Sleep Apnoea | 4% | |
| Pulmonary Sarcoidosis | 4% | |
| Psychiatric Comorbidities (including Substance Abuse) | Emotionally Instable Personality Disorder | 16% |
| Current Alcohol Misuse | 16% | |
| Post Traumatic Stress Disorder | 8% | |
| Somatoform Disorder | 4% | |